ライフサイエンスコーパス: humoral rejection

1 might be effective in patients with 'chronic humoral rejection'.

2 tion despite treatment with cyclosporine, or humoral rejection.

3 he interferon-gamma may reflect this ongoing humoral rejection.

4 long graft survival times without immediate humoral rejection.

5 kidney transplant recipients with stable or humoral rejection.

6 ular rejection with immunohistochemistry for humoral rejection.

7 ones from a kidney transplant recipient with humoral rejection.

8 hat posttransplant capillaritis is a form of humoral rejection.

9 2 cases; the other nine had evidence only of humoral rejection.

10 estration of DSAs protects islet grafts from humoral rejection.

11 d group antibody titers are at high risk for humoral rejection.

12 et graft attrition, suggesting resistance to humoral rejection.

13 e endothelial deposition of C4d, a marker of humoral rejection.

14 lly reduced both DSAs and NDSAs and reversed humoral rejection.

15 ays an important role in initiation of acute humoral rejection.

16 jection, acute humoral rejection and chronic humoral rejection.

17 lantation to elucidate the initial stages of humoral rejection.

18 ifficult barrier to organ transplantation is humoral rejection, a condition initiated by binding of a

19 Acute vascular or humoral rejection, a vexing outcome of organ transplanta

20 ficity of C4d staining as a marker for acute humoral rejection ACR in renal allografts, indirect immu

21 nts do not control the vigorous cellular and humoral rejection across species disparities.

22 anti-pig antibody leads to a delayed form of humoral rejection, acute humoral xenograft rejection, wh

23 .06-1.16; P < 0.001), severe vascular and/or humoral rejection (adjusted odds ratio, 1.06; 95% CI, 1.

24 (16.3 %) patients were diagnosed with acute humoral rejection (AHR) and 11/49 (22.4%) patients were

25 The distinction between acute humoral rejection (AHR) and acute cellular rejection (AC

26 Acute humoral rejection (AHR) has been associated with enhance

27 Standard therapy for acute humoral rejection (AHR) has been removal of donor-specif

28 The incidence of acute humoral rejection (AHR) in renal allograft biopsies has

29 Hyperacute rejection (HAR) and acute humoral rejection (AHR) remain recalcitrant conditions w

30 Acute humoral rejection (AHR), which occurs in up to 8% of kid

31 aft loss and the secondary outcome was acute humoral rejection (AHR).

32 donor-specific antibodies, a cause of acute humoral rejection (AHR).

33 opment of donor-specific alloantibody (acute humoral rejection, AHR) typically carries a poor prognos

34 entity that carries a poor prognosis (acute humoral rejection, AHR).

35 Acute humoral rejection, also known as acute vascular rejectio

36 for the newly appreciated conditions chronic humoral rejection and accommodation.

37 by B lymphocytes, which may lead to chronic humoral rejection and allograft failure.

38 hree categories: hyperacute rejection, acute humoral rejection and chronic humoral rejection.

39 cal pathways discriminate acute cellular and humoral rejection and DGF.

40 s, because they are strongly associated with humoral rejection and graft loss.

41 graft rejection, may be high at the time of humoral rejection and may not be elevated in cellular re

42 ent regimen tested here consistently prevent humoral rejection and systemic coagulation pathway dysre

43 eterioration include subclinical cellular or humoral rejection, and chronic calcineurin inhibitor tox

44 Sixteen animals showed humoral rejection, and in all but two animals one or mor

45 bulin G, had biopsy findings consistent with humoral rejection, and showed rapidly progressive xenogr

46 1, n = 50) had a biopsy highly suggestive of humoral rejection, and the second (G2, n = 50) had no cr

47 y understanding of the pathogenesis of acute humoral rejection, and to developing means of preventing

48 Current treatment options for humoral rejection are limited by a lack of specific anti

49 C4d is a specific marker for the presence of humoral rejection, as indicated by its association with

50 ably for 6 weeks and manifest no cellular or humoral rejection at that time.

51 There were no humoral rejections based on ABO-antigen-antibody interac

52 antibodies to function not only in classical humoral rejection but also as opsonins that facilitate t

53 in renal allograft recipients with 'chronic humoral rejection' by using an immunosuppressive regimen

54 In patients with biopsy-diagnosed humoral rejection (C4d+), serum levels of both DSA and N

55 Patients with humoral rejection can be identified with high sensitivit

56 The T2 average in humoral rejection cases (n=2) was 59.2+/-3.3 ms and the

57 m the engineered pigs are resistant to human humoral rejection, cell-mediated damage and pathogenesis

58 he following histological diagnoses: chronic humoral rejection (CHR) (n=44), IF/TA (n=42), recurrence

59 eir transplant acutely but developed chronic humoral rejection (CHR) and in tolerant recipients (n =

60 Chronic humoral rejection (CHR) is a major complication after ki

61 Humoral rejection correlated with the baseline antibody

62 Further strategies to address humoral rejection could prolong graft survival and resul

63 ibodies are rarely detected, suggesting that humoral rejection does not play a significant role in co

64 t capillary-bound C4d is a robust marker for humoral rejection has started a new investigation into t

65 Most humoral rejection (HR) episodes occur early after cardia

66 usually either recurrent TMA (RecTMA) due to humoral rejection (HR-TMA) or due to calcineurin inhibit

67 ure (>20% increase in creatinine levels) and humoral rejection in graft pathology.

68 -type (WT) grafts showed hyperacute or acute humoral rejection in nonsensitized GalT KO mice with low

69 es did not correlate with the development of humoral rejection in the early posttransplant period.

70 te the physiologic role of DAF in preventing humoral rejection in the presence of low levels of NAb a

71 dies are consistent with a paradigm of acute humoral rejection in which CD4(+) T cell-dependent alloa

72 otection from infections, acute cellular and humoral rejections in patients with hypogammaglobulinemi

73 be a sensitive marker for antibody-mediated (humoral) rejection in renal transplant biopsies.

74 monstrating features consistent with delayed humoral rejection, including reactive vascular endotheli

75 Despite the recognition that humoral rejection is an important cause of allograft inj

76 Humoral rejection is associated with increased graft los

77 Evidence of acute cellular with occult humoral rejection is identified in more than 40% of late

78 Fortunately, humoral rejection is not the only outcome of antibody bi

79 Humoral rejection is the most common cause of solid orga

80 The hallmark of humoral rejection is the presence of subendothelial C4d

81 By 34 days, acute humoral rejection led to xenograft loss in all three xen

82 Late acute humoral rejection may be associated with interstitial he

83 Only one acute humoral rejection occurred 8 days after transplantation,

84 Humoral rejection occurred in 18% nonsplenectomized and

85 Humoral rejection occurred in one patient whereas acute

86 Irreversible humoral rejection occurred in one patient.

87 Humoral rejection occurs now more frequently in patients

88 We showed that humoral rejection of a kidney allograft is associated wi

89 However, humoral rejection of both DAF KO and DAF WT donor grafts

90 etic engineering of bone marrow may overcome humoral rejection of discordant xenografts and may be us

91 ng peritubular capillaries (PC) may indicate humoral rejection of renal allografts.

92 renal allografts as a result of cellular and humoral rejection on days 140, 89, and 84.

93 lso suggest that C4d in PTCs is specific for humoral rejection or, at least, for the presence of dono

94 prolonged graft survival, slowly progressive humoral rejection--probably associated with non-Gal anti

95 (> or =1:256) appear to be at high risk for humoral rejection regardless of protocol used.

96 mediated rejection, acute antibody-mediated (humoral) rejection, rejection mediated by the innate imm

97 r-old woman with hemodynamically significant humoral rejection resistant to steroids, cyclophos-phami

98 useful to prevent the vigorous cellular and humoral rejection response to xenografts.

99 be partially responsible for the absence of humoral rejection resulting from ABO-antigen-antibody in

100 recipients predisposed to acute cellular and humoral rejection, that is, children with intestinal tra

101 cognition is important in the development of humoral rejection; therefore, there is an increasing int

102 ith additional strategies aimed at silencing humoral rejection, VTL transplantation may significantly

103 or B-cell responses in recipients with acute humoral rejection, we sought to determine whether a simi

104 vascular lesions that can be associated with humoral rejection were not more frequent in the antibody

105 our renal allograft recipients with 'chronic humoral rejection' were prospectively identified.

106 This article reviews the features of humoral rejection, which we believe is responsible for m

107 Liver biopsies were routinely stained for humoral rejection with complement 4d (C4d) and for bilia

108 Donor organs showed progressive acute humoral rejection with deposits of IgM, IgG, and complem

109 was associated with the development of acute humoral rejection with features of coagulopathy.